Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Aptose Biosciences Announces Approval For Listing On The Capital Market Shares To Begin Trading Under The Symbol APTO

October 21, 2014 – 5:00 am | Edit Post

SAN DIEGO and TORONTO, Oct. 21, 2014 /PRNewswire/ – Aptose Biosciences Inc. (Aptose) (TSX:APS), a clinical-stage company developing targeted agents and molecular diagnostics to treat the underlying mechanisms of cancer, announced today that its common shares…

Neurocrine Biosciences, Inc. Announces Initiation Of Phase 3 Study For VMAT2 Inhibitor NBI-98854

October 21, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 20, 2014 /PRNewswire/ –Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase III clinical trial (Kinect 3 Study) of its proprietary Vesicular Monoamine Transporter 2 compound, NBI-98854. The design of the Kinect 3 Study is a randomized, parallel-group, double…

Contract Research Organization Announces Clinical Trial Patient Rescue Program With A Pay-Per-Patient Enrolled Pricing Structure

October 21, 2014 – 5:00 am | Edit Post

COSTA MESA, Calif., Oct. 21, 2014 /PRNewswire-iReach/ — WCCT Global, a full service contract research organization headquartered in Southern California announced today the launch of a clinical trial patient recruitment…

Immunotech Laboratories Enters Into Agreement To Market Potential Ebola Virus Disease (???EVD???) Treatment And Implement Strategy For Company’s ITV-1 Infectious Diseases Treatment In Africa

October 21, 2014 – 5:00 am | Edit Post

MONROVIA, Calif.–(BUSINESS WIRE)–Immunotech Laboratories, Inc. (OTC PINK: IMMB) (Immunotech or the Company) and wholly-owned subsidiary Immunotech Laboratories, BG (IMMB-BG) today announced that they have successfully completed negotiations with Uldic Investment Pvt. Ltd. (Uldic), located in Zimbabwe, to pursue the development of market opportunities related to the deadly Ebola virus, and to…

Illumina, Inc. Reports Record Financial Results For Third Quarter Of Fiscal Year 2014

October 21, 2014 – 5:00 am | Edit Post

Illumina, Inc. (NASDAQ:ILMN) today announced its financial results for the third quarter of 2014. Third quarter 2014 results: Revenue of $481 million, a 35% increase compared to $357 million in the third quarter of 2013 Help employers find you! Check out all the jobs and…

Ivera Medical Corporation Successfully Completes FDA Inspection

October 21, 2014 – 5:00 am | Edit Post

SAN DIEGO, CA–(Marketwired – Oct 21, 2014) – Ivera Medical Corporation is pleased to report that it successfully completed several days of an exhaustive and intensive review by the Food and Drug Administration (FDA) of Ivera’s manufacturing practices, quality control and regulatory filings. At the conclusion of the inspection, which was prompted by a complaint filed by a competitor (Catheter Connections…

Cytori Therapeutics, Inc. Announces Resignation Of Effective November 1, 2014

October 21, 2014 – 5:00 am | Edit Post

The Board of Directors of Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that Lloyd H. Dean has tendered his resignation as a member of the Board, effective November 1, 2014. Mr. Dean has served as a director of the Company since 2010 and served as Chairman of the Companys Board of Directors from April 2011 until June 2013. Help employers find you! Check out all the

Inogen Announces Release To Market Of The At Home, An Innovative Home Oxygen Concentrator

October 21, 2014 – 5:00 am | Edit Post

GOLETA, Calif., Oct. 21, 2014 (GLOBE NEWSWIRE) — Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the…

Sequenom, Inc. Announces Date Of Third Quarter 2014 Financial Results And Conference Call

October 21, 2014 – 4:00 am | Edit Post

SAN DIEGO, Oct. 21, 2014 /PRNewswire/ – Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced it will report financial results for the third quarter 2014 after closing of the NASDAQ Global Market on Tuesday, November 4, 2014.  

A conference call hosted by William Welch, CEO, and other members of senior management will take place on Tuesday, November 4, 2014, at 5:00 p.m. EDT (2:00 p.m. PDT) and will be webcast live on the Sequenom Website.

To access the live teleconference call, dial 877-883-0383 in the U.S. and Canada, and 412-902-6506 for other international callers. Please use code 0747050. For interested parties unable to listen to the live conference call, a replay will be available through Friday, December 5, 2014. The replay will be accessible by dialing 877-344-7529 or 412-317-0088 international toll or Canada toll free at 855-669-9658, and entering the conference number 10054723.

The conference call webcast is also accessible through the “Invest” section of the Sequenom Website at www.sequenom.com/invest. An online replay will be available following the initial broadcast until Friday, December 5, 2014. 

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving health care through revolutionary genomic and genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve molecular diagnostic markets. Web site: www.sequenom.com.  

Logo – http://photos.prnewswire.com/prnh/20040415/SQNMLOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sequenom-inc-announces-date-of-third-quarter-2014-financial-results-and-conference-call-848332976.html
SOURCE Sequenom, Inc.

Ivera Medical Successfully Completes FDA Inspection

October 21, 2014 – 2:00 am | Edit Post

SAN DIEGO, CA–(Marketwired – Oct 21, 2014) – Ivera Medical Corporation is pleased to report that it successfully completed several days of an exhaustive and intensive review by the Food and Drug Administration (FDA) of Ivera’s manufacturing practices, quality control and regulatory filings. At the conclusion of the inspection, which was prompted by a complaint filed by a competitor (Catheter Connections), the inspector found that no corrective actions were needed. Ivera recently received a copy of the inspection report from the local FDA District Office confirming that the inspection is now considered officially closed.